Corinna Sison, MD

All articles by Corinna Sison, MD


WASHINGTON, DC — Treatment of psoriatic arthritis (PsA) with ixekizumab (IXE)—an IgG4 monoclonal antibody—significantly improves arthritis, dactylitis and enthesitis at 52-weeks, according to research presented at the 2016 American College of Rheumatology Annual Meeting. Philip J Mease, MD, at the Swedish Medical Center and the University of Washington, and colleagues conducted a phase 3 study…